Pipelines

Fast track status for Novartis MAb Bimagrumab

FDA Grants Novartis Biologic Breakthrough Status

By Dan Stanton

A third Novartis biopharmaceutical has received breakthrough designation status from the FDA allowing ‘fast-track’ development and review without compromising safety, the company says.

Follow us

Products

View more

Webinars